An Open-Label, Multicentre Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Official Title

A Phase Ib/II Open-Label, Multicentre Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Summary:

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.

Trial Description

Primary Outcome:

  • Percentage of Participants with Adverse Events (Phase 1b)
  • Best Objective Response Rate (ORR) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)
Secondary Outcome:
  • Best ORR as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b)
  • Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b and Phase 2)
  • Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b and Phase 2)
  • Progression-Free Survival (PFS) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)
  • Event-Free Survival (EFS) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)
  • Overall Survival (OS) (Phase 2)
  • Percentage of Participants with Adverse Events (Phase 2)
  • Serum Concentration of Mosunetuzumab
  • Serum Concentration of Mosunetuzumab in Combination with Tiragolumab
  • Serum Concentration of Mosunetuzumab in Combination with Tiragolumab and Atezolizumab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society